Skip to content
BALCAO · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · SMALL CAP

Stemtech Corp. STEK

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.9M
▼ 43.1% YoY
$-4.0M
$-483,583

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 2.9M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 2.9 · Net income -4.0
2M4M-3M-6M
201020132016201920222025
Compound annual growth
−14.2%
−8.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −8.1% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−141 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -94.2% · Net -140.8%
-50%-100%-150%
201020172025
ROE

No chart to show — the reason differs by year; see each year in the table below.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -0.5
-1M-2M
201020172025

Total assetsUSD 3.1M
EquityUSD -7.0M
CashUSD 238,245.00
Gross debtUSD 4.2M
Net debtUSD 3.9M
Current ratio0.04×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
STEK, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.0◌◌◌◌◌◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌◌◌◌◌◌
Income tax $B0.00.00.00.00.0−0.0◌◌◌◌◌0.00.0◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0◌◌−0.0◌◌◌◌◌◌◌◌◌◌
EPS, diluted $−0.02−0.03−0.07−0.19−0.20−0.10−0.00−0.00−0.00−0.00−0.00−0.00−0.00−0.00◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %——————————————◌◌
Shares out B0.430.140.100.050.040.03◌◌◌◌◌◌◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 64 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. 13 checks were skipped: revenue is not tagged before 2020. 10 checks were skipped: the balance sheet is not tagged before 2012. Five checks were skipped: EPS is not tagged before 2012.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityWholesale-Drugs, Proprietaries & Druggists' Sundries
Listed onOTC market
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2010

Share this section

Download image